Precipio, Inc.·Healthcare

Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript

Precipio (NASDAQ: PRPO - Get Free Report) and Healthcare Triangle (NASDAQ: HCTI - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Risk and Volatility Precipio has a beta of

NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET.

Precipio (NASDAQ: PRPO - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of recent ratings

In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M

Precipio, Inc. (NASDAQ: PRPO - Get Free Report) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 4,048 shares, a growth of 22.5% from the January 15th total of 3,304 shares. Based on an average daily trading volume, of 10,844 shares, the short-interest ratio is presently 0.4
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Healthcare
Medical - Diagnostics & Research
54
2017-06-30
1.20